Trial watch: dendritic cell vaccination for cancer immunotherapy
| العنوان: | Trial watch: dendritic cell vaccination for cancer immunotherapy |
|---|---|
| المؤلفون: | Steven De Vleeschouwer, Laurence Zitvogel, Jenny Sprooten, Abhishek D. Garg, An Coosemans, Guido Kroemer, Jolien Ceusters, Lorenzo Galluzzi, Patrizia Agostinis |
| المصدر: | OncoImmunology, Vol 8, Iss 11 (2019) Oncoimmunology |
| بيانات النشر: | TAYLOR & FRANCIS INC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | lcsh:Immunologic diseases. Allergy, 0301 basic medicine, RESISTANT PROSTATE-CANCER, medicine.medical_treatment, Immunology, ALPHA-GALACTOSYLCERAMIDE, Context (language use), Review, SIPULEUCEL-T, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, PHASE-I TRIAL, Cancer immunotherapy, Antigen, INTRATUMORAL INJECTION, medicine, Immunology and Allergy, Cytotoxic T cell, DAMPs, Science & Technology, CROSS-PRESENTATION, business.industry, Tumor-infiltrating lymphocytes, tlr signaling, CYTOTOXIC T-LYMPHOCYTES, TLR signaling, clinical trial, Dendritic cell, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, PANCREATIC-CANCER, immune checkpoint blockers, Clinical trial, Vaccination, 030104 developmental biology, Antigen cross-presentation, Oncology, plasmacytoid dendritic cells, 030220 oncology & carcinogenesis, tumor-infiltrating lymphocytes, ANTITUMOR IMMUNE-RESPONSES, damps, antigen cross-presentation, lcsh:RC581-607, business, Life Sciences & Biomedicine, APOPTOTIC TUMOR-CELLS |
| الوصف: | Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology. ispartof: ONCOIMMUNOLOGY vol:8 issue:11 ispartof: location:United States status: published |
| وصف الملف: | Electronic-eCollection |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1151ec5abe3231ca58c7c0745b450fTest https://lirias.kuleuven.be/handle/123456789/640263Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1b1151ec5abe3231ca58c7c0745b450f |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |